Total Payments
$384,580
2024 Payments
$44,573
Companies
14
Transactions
87
Medicare Patients
1,412
Medicare Billing
$242,796
Payment Breakdown by Category
Research$296,365 (77.1%)
Consulting$83,884 (21.8%)
Travel$3,336 (0.9%)
Food & Beverage$675.14 (0.2%)
Other$320.12 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $296,365 | 22 | 77.1% |
| Consulting Fee | $83,884 | 30 | 21.8% |
| Travel and Lodging | $3,336 | 18 | 0.9% |
| Food and Beverage | $675.14 | 15 | 0.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $228.66 | 1 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91.46 | 1 | 0.0% |
Payments by Type
Research
$296,365
22 transactions
General
$88,215
65 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ichnos Sciences Inc. | $198,252 | 15 | $0 (2023) |
| Glenmark Pharmaceuticals Inc. | $68,139 | 5 | $0 (2018) |
| GENZYME CORPORATION | $41,246 | 24 | $0 (2024) |
| IGI Inc | $29,974 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $10,920 | 7 | $0 (2022) |
| Celgene Corporation | $9,077 | 7 | $0 (2017) |
| GlaxoSmithKline, LLC. | $8,825 | 6 | $0 (2021) |
| Legend Biotech USA Inc. | $8,549 | 7 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $5,390 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,615 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,573 | 15 | IGI Inc ($29,974) |
| 2023 | $24,275 | 10 | Ichnos Sciences Inc. ($21,007) |
| 2022 | $37,788 | 10 | Ichnos Sciences Inc. ($25,640) |
| 2021 | $45,453 | 10 | Ichnos Sciences Inc. ($34,075) |
| 2020 | $130,017 | 11 | Ichnos Sciences Inc. ($117,529) |
| 2019 | $10,197 | 10 | GENZYME CORPORATION ($8,194) |
| 2018 | $83,199 | 14 | Glenmark Pharmaceuticals Inc. ($68,139) |
| 2017 | $9,077 | 7 | Celgene Corporation ($9,077) |
All Payment Transactions
87 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,909.00 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $22.80 | General |
| 09/05/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 07/22/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $29.05 | General |
| Category: Oncology | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,909.00 | General |
| Category: Oncology | ||||||
| 05/22/2024 | IGI Inc | — | — | Cash or cash equivalent | $17,292.80 | Research |
| Study: ISB 1342-101 | ||||||
| 04/10/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Consulting Fee | Cash or cash equivalent | $7,880.00 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Travel and Lodging | In-kind items and services | $26.80 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Travel and Lodging | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: Oncology | ||||||
| 03/22/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Travel and Lodging | In-kind items and services | $549.20 | General |
| Category: Oncology | ||||||
| 03/22/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Food and Beverage | In-kind items and services | $44.73 | General |
| Category: Oncology | ||||||
| 03/04/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Oncology | ||||||
| 02/02/2024 | IGI Inc | — | — | Cash or cash equivalent | $12,681.00 | Research |
| Study: ISB 1342-101 | ||||||
| 10/27/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $23.43 | General |
| 10/10/2023 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $228.66 | General |
| 10/02/2023 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $91.46 | General |
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $63.33 | General |
| 10/02/2023 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | In-kind items and services | $25.33 | General |
| 05/30/2023 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Consulting Fee | In-kind items and services | $1,000.00 | General |
| Category: Oncology | ||||||
| 05/11/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $745.00 | General |
| Category: Oncology | ||||||
| 03/30/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $8,763.30 | Research |
| Study: ISB 1342-101 | ||||||
| 02/27/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $12,244.00 | Research |
| Study: ISB 1342-101 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $198,252 | 15 |
| ISB 1342-101 | IGI Inc | $29,974 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 350 | 623 | $218,896 | $59,826 |
| 2022 | 4 | 354 | 658 | $187,647 | $64,375 |
| 2021 | 5 | 366 | 698 | $190,313 | $66,003 |
| 2020 | 4 | 342 | 643 | $181,866 | $52,592 |
Total Patients
1,412
Total Services
2,622
Medicare Billing
$242,796
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 95 | 229 | $91,055 | $26,560 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 103 | 152 | $44,362 | $11,037 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 68 | 125 | $36,733 | $9,496 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 57 | $22,510 | $6,607 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $21,717 | $5,544 | 25.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 12 | 22 | $2,519 | $580.54 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 96 | 183 | $58,899 | $21,489 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 59 | 106 | $34,116 | $12,428 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 82 | 147 | $35,023 | $11,434 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 152 | $36,214 | $11,065 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $13,367 | $4,401 | 32.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 41 | $10,029 | $3,558 | 35.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 68 | 157 | $50,530 | $17,772 | 35.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 78 | 140 | $45,059 | $17,105 | 38.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 141 | $33,593 | $11,328 | 33.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 138 | $32,879 | $10,450 | 31.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 27 | 27 | $12,445 | $4,221 | 33.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 41 | $10,029 | $3,670 | 36.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 15 | 34 | $3,638 | $952.92 | 26.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 13 | 20 | $2,140 | $504.51 | 23.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 110 | 257 | $82,715 | $22,599 | 27.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 54 | 107 | $34,438 | $10,360 | 30.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 70 | 122 | $29,067 | $7,889 | 27.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 48 | 76 | $18,107 | $4,731 | 26.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 39 | 60 | $7,860 | $3,985 | 50.7% |
About Dr. Carol Huff, M.D
Dr. Carol Huff, M.D is a Medical Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205882024.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carol Huff, M.D has received a total of $384,580 in payments from pharmaceutical and medical device companies, with $44,573 received in 2024. These payments were reported across 87 transactions from 14 companies. The most common payment nature is "" ($296,365).
As a Medicare-enrolled provider, Huff has provided services to 1,412 Medicare beneficiaries, totaling 2,622 services with total Medicare billing of $242,796. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Baltimore, MD
- Active Since 05/25/2006
- Last Updated 02/08/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1205882024
Products in Payments
- ISB 1342-101 (Drug) $117,529
- SARCLISA (Biological) $21,142
- CD38 (Drug) $20,104
- Revlimid (Drug) $9,077
- CARVYKTI (Biological) $8,549
- DARZALEX (Biological) $8,170
- DARZALEX (Drug) $3,150
- TECVAYLI (Biological) $2,750
- BLENREP (Biological) $1,625
- CARVYKTI (Drug) $1,000
- GENEXPERT (Device) $393.00
- TALVEY (Biological) $150.00
- Onivyde (Drug) $59.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Baltimore
Mario Eisenberger, M.d, M.D
Medical Oncology — Payments: $2.9M
Medical Oncology $2.9M
Dr. Tanguy Seiwert, M.d, M.D
Medical Oncology — Payments: $622,422
Medical Oncology $622,422
Carole Miller, Md, MD
Medical Oncology — Payments: $587,841
Medical Oncology $587,841
Bruce Smith, M.d, M.D
Medical Oncology — Payments: $406,689
Medical Oncology $406,689
Leisha Emens
Medical Oncology — Payments: $252,501
Medical Oncology $252,501
Enser Cole, Md, MD
Medical Oncology — Payments: $220,743
Medical Oncology $220,743